These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8244163

  • 21. Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma.
    Strauss G, Lund B, Hansen M, Hansen HH.
    Gynecol Oncol; 1997 Jul; 66(1):66-70. PubMed ID: 9234923
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Ifosfamide with mesna uroprotection in the management of lung cancer.
    Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK, Umsawasdi T, Levy JK, Jeffries D, Raber MN, Hong WK.
    Am J Clin Oncol; 1990 Apr; 13(2):148-55. PubMed ID: 2156418
    [Abstract] [Full Text] [Related]

  • 25. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
    Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C.
    Gynecol Oncol; 2007 May 15; 105(2):399-403. PubMed ID: 17292457
    [Abstract] [Full Text] [Related]

  • 28. New options for the treatment of advanced ovarian cancer.
    Dunton CJ.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [Abstract] [Full Text] [Related]

  • 29. Chemotherapy for advanced ovarian cancer: overview of randomized trials.
    Thigpen JT.
    Semin Oncol; 2000 Jun 15; 27(3 Suppl 7):11-6. PubMed ID: 10952121
    [Abstract] [Full Text] [Related]

  • 30. Ifosfamide and Mesna in advanced malignancies.
    Li GC, Brock N, Li JQ, Guan ZZ, He YJ.
    Chin Med J (Engl); 1988 Mar 15; 101(3):213-20. PubMed ID: 3136996
    [No Abstract] [Full Text] [Related]

  • 31. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R.
    Cancer Treat Rep; 1979 Mar 15; 63(3):501-5. PubMed ID: 106965
    [Abstract] [Full Text] [Related]

  • 32. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
    Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C.
    Cancer Invest; 2006 Feb 15; 24(1):22-7. PubMed ID: 16466988
    [Abstract] [Full Text] [Related]

  • 33. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Cancer Chemother Pharmacol; 1990 Feb 15; 26 Suppl():S55-8. PubMed ID: 2112054
    [Abstract] [Full Text] [Related]

  • 34. The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix.
    Thigpen T, Vance R, Khansur T, Malamud F.
    Semin Oncol; 1996 Jun 15; 23(3 Suppl 6):56-64. PubMed ID: 8677451
    [Abstract] [Full Text] [Related]

  • 35. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.
    Cancer; 2003 Jul 15; 98(2):331-6. PubMed ID: 12872353
    [Abstract] [Full Text] [Related]

  • 36. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M.
    Gynecol Oncol; 2000 Aug 15; 78(2):221-7. PubMed ID: 10926807
    [Abstract] [Full Text] [Related]

  • 37. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A.
    Semin Oncol; 2000 Feb 15; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [Abstract] [Full Text] [Related]

  • 38. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC, Sill M, Hoffman JS, Bender DP, Gynecologic Oncology Group.
    Gynecol Oncol; 2008 May 15; 109(2):182-6. PubMed ID: 18295319
    [Abstract] [Full Text] [Related]

  • 39. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF.
    Urology; 2007 Feb 15; 69(2):255-9. PubMed ID: 17320659
    [Abstract] [Full Text] [Related]

  • 40. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P, GONO (Italian Gruppo Oncologico del Nord-Ovest).
    Gynecol Oncol; 2004 May 15; 93(2):474-8. PubMed ID: 15099965
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.